On Nov 10, 2018 Tracon Pharmaceuticals Inc (NASDAQ:TCON) Sellers Increased Their Shorts By 11.92%

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Corporate Logo

Tracon Pharmaceuticals Inc (NASDAQ:TCON) had an increase of its shares shorted by 11.92%. In November was announced TCON’s total 205,700 shares shorted by FINRA. That’s 11.92% up from 183,800 shares. 2 days will cost TCON with 119,900 average volume to recover its previous position. Tracon Pharmaceuticals Inc float short is 1.42%.

TCON reached $1.43 during the last trading session after $0.07 change.TRACON Pharmaceuticals, Inc. has 107,287 shares volume, 8.53% up from normal. TCON is downtrending and has moved 34.33% since November 10, 2017. TCON underperformed the S&P500 by 49.95%.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The firm is worth $42.67 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Currently it has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

For more TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news posted briefly go to: Uk.Finance.Yahoo.com, Benzinga.com, Benzinga.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Shareholders Should Check The Ownership Structure Of TRACON Pharmaceuticals Inc (NASDAQ:TCON)” posted on October 15, 2018, “The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie” on November 07, 2018, “The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs” with a publish date: November 04, 2018, “TRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018” and the last “TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q3 2018 Results – Earnings Call Transcript” with publication date: November 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.